|
|
Vaccine Detail
|
live attenuated Brucella melitensis strain M5-90 phosphoglucomutase mutant vaccine |
| Vaccine Information |
- Vaccine Name: live attenuated Brucella melitensis strain M5-90 phosphoglucomutase mutant vaccine
- Target Pathogen: Brucella spp.
- Target Disease: Brucellosis
- Vaccine Ontology ID: VO_0009359
- Type: Live attenuated vaccine
- Status: Research
- Host Species for Licensed Use: Goat
- Host Species as Laboratory Animal Model: BALB/c mice; embryonic trophoblast cells; sheep
- Antigen: phosphoglucomutase (PGM) mutant
- Preparation: Live attenuated mutant strain with deletion of phosphoglucomutase gene. (Zhang et al, 2016)
- Description: A Brucella melitensis strain M5-90 pgm mutant (M5-90Δpgm) was constructed to overcome drawbacks of residual virulence and serological differentiation issues of existing live attenuated vaccines. Efficacy: M5-90Δpgm showed significantly reduced survival in cells and mice and induced high protective immunity in BALB/c mice against wild-type challenge. Immune response: Induced anti-Brucella-specific immunoglobulin G response; secretion of gamma interferon (IFN-γ) and interleukin-2 (IL-2) in mice; IFN-γ secretion in immunized sheep; allowed serological differentiation between infected and vaccinated animals. (Zhang et al, 2016)
|
| Host Response |
|
|
| References |
Zhang et al, 2016: Zhang Y, Li T, Zhang J, Li Z, Zhang Y, Wang Z, Feng H, Wang Y, Chen C, Zhang H. The Brucella melitensis M5-90 phosphoglucomutase (PGM) mutant is attenuated and confers protection against wild-type challenge in BALB/c mice. World journal of microbiology & biotechnology. 2016 Apr; 32(4); 58. [PubMed: 26925620].
|
|
